126 related articles for article (PubMed ID: 34303194)
1. IGFBP7 overexpression promotes acquired resistance to AZD9291 in non-small cell lung cancer.
Tang X; Mu J; Ma L; Tan Q; Wang J; Tan J; Zhang S
Biochem Biophys Res Commun; 2021 Sep; 571():38-45. PubMed ID: 34303194
[TBL] [Abstract][Full Text] [Related]
2. Loss of EGFR confers acquired resistance to AZD9291 in an EGFR-mutant non-small cell lung cancer cell line with an epithelial-mesenchymal transition phenotype.
Xu J; Zhao X; He D; Wang J; Li W; Liu Y; Ma L; Jiang M; Teng Y; Wang Z; Gu M; Wu J; Wang Y; Yue W; Zhang S
J Cancer Res Clin Oncol; 2018 Aug; 144(8):1413-1422. PubMed ID: 29797219
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive analysis of circular RNA profiling in AZD9291-resistant non-small cell lung cancer cell lines.
Chen T; Luo J; Gu Y; Huang J; Luo Q; Yang Y
Thorac Cancer; 2019 Apr; 10(4):930-941. PubMed ID: 30883029
[TBL] [Abstract][Full Text] [Related]
4. Activation of insulin-like growth factor-1 receptor confers acquired resistance to osimertinib in non-small cell lung cancer with EGFR T790M mutation.
Hayakawa D; Takahashi F; Mitsuishi Y; Tajima K; Hidayat M; Winardi W; Ihara H; Kanamori K; Matsumoto N; Asao T; Ko R; Shukuya T; Takamochi K; Hayashi T; Suehara Y; Takeda Nakamura I; Ueno T; Kohsaka S; Mano H; Takahashi K
Thorac Cancer; 2020 Jan; 11(1):140-149. PubMed ID: 31758670
[TBL] [Abstract][Full Text] [Related]
5. Acquired resistance to AZD9291 as an upfront treatment is dependent on ERK signaling in a preclinical model.
Ku BM; Choi MK; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
PLoS One; 2018; 13(4):e0194730. PubMed ID: 29641535
[TBL] [Abstract][Full Text] [Related]
6. Increased Expression of IRE1α Associates with the Resistant Mechanism of Osimertinib (AZD9291)-resistant non-small Cell Lung Cancer HCC827/OSIR Cells.
Tang ZH; Su MX; Guo X; Jiang XM; Jia L; Chen X; Lu JJ
Anticancer Agents Med Chem; 2018; 18(4):550-555. PubMed ID: 28730963
[TBL] [Abstract][Full Text] [Related]
7. SHR-A1403, a novel c-mesenchymal-epithelial transition factor (c-Met) antibody-drug conjugate, overcomes AZD9291 resistance in non-small cell lung cancer cells overexpressing c-Met.
Tong M; Gao M; Xu Y; Fu L; Li Y; Bao X; Fu H; Quan H; Lou L
Cancer Sci; 2019 Nov; 110(11):3584-3594. PubMed ID: 31446643
[TBL] [Abstract][Full Text] [Related]
8. Overcoming acquired resistance of gefitinib in lung cancer cells without T790M by AZD9291 or Twist1 knockdown in vitro and in vivo.
Liu Z; Gao W
Arch Toxicol; 2019 Jun; 93(6):1555-1571. PubMed ID: 30993382
[TBL] [Abstract][Full Text] [Related]
9. Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment.
Shi P; Oh YT; Zhang G; Yao W; Yue P; Li Y; Kanteti R; Riehm J; Salgia R; Owonikoko TK; Ramalingam SS; Chen M; Sun SY
Cancer Lett; 2016 Oct; 380(2):494-504. PubMed ID: 27450722
[TBL] [Abstract][Full Text] [Related]
10. DYRK1A inhibition suppresses STAT3/EGFR/Met signalling and sensitizes EGFR wild-type NSCLC cells to AZD9291.
Li YL; Ding K; Hu X; Wu LW; Zhou DM; Rao MJ; Lin NM; Zhang C
J Cell Mol Med; 2019 Nov; 23(11):7427-7437. PubMed ID: 31454149
[TBL] [Abstract][Full Text] [Related]
11. AZD9291 overcomes T790 M-mediated resistance through degradation of EGFR(L858R/T790M) in non-small cell lung cancer cells.
Ku BM; Bae YH; Koh J; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
Invest New Drugs; 2016 Aug; 34(4):407-15. PubMed ID: 27044261
[TBL] [Abstract][Full Text] [Related]
12. Identification of osimertinib (AZD9291) as a lysine specific demethylase 1 inhibitor.
Li ZR; Suo FZ; Hu B; Guo YJ; Fu DJ; Yu B; Zheng YC; Liu HM
Bioorg Chem; 2019 Mar; 84():164-169. PubMed ID: 30502627
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of MEK5/ERK5 signaling overcomes acquired resistance to the third generation EGFR inhibitor, osimertinib, via enhancing Bim-dependent apoptosis.
Zhao W; Yu D; Chen Z; Yao W; Yang J; Ramalingam SS; Sun SY
Cancer Lett; 2021 Oct; 519():141-149. PubMed ID: 34245854
[TBL] [Abstract][Full Text] [Related]
14. Hypoxia Induces Resistance to EGFR Inhibitors in Lung Cancer Cells via Upregulation of FGFR1 and the MAPK Pathway.
Lu Y; Liu Y; Oeck S; Zhang GJ; Schramm A; Glazer PM
Cancer Res; 2020 Nov; 80(21):4655-4667. PubMed ID: 32873635
[TBL] [Abstract][Full Text] [Related]
15. Synergistic effects of Bcl-2 inhibitors with AZD9291 on overcoming the acquired resistance of AZD9291 in H1975 cells.
Liu Z; Gao W
Arch Toxicol; 2020 Sep; 94(9):3125-3136. PubMed ID: 32577785
[TBL] [Abstract][Full Text] [Related]
16. Characterization of osimertinib (AZD9291)-resistant non-small cell lung cancer NCI-H1975/OSIR cell line.
Tang ZH; Jiang XM; Guo X; Fong CM; Chen X; Lu JJ
Oncotarget; 2016 Dec; 7(49):81598-81610. PubMed ID: 27835594
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms of Acquired Resistance to AZD9291: A Mutation-Selective, Irreversible EGFR Inhibitor.
Kim TM; Song A; Kim DW; Kim S; Ahn YO; Keam B; Jeon YK; Lee SH; Chung DH; Heo DS
J Thorac Oncol; 2015 Dec; 10(12):1736-44. PubMed ID: 26473643
[TBL] [Abstract][Full Text] [Related]
18. Osimertinib (AZD9291) decreases programmed death ligand-1 in EGFR-mutated non-small cell lung cancer cells.
Jiang XM; Xu YL; Huang MY; Zhang LL; Su MX; Chen X; Lu JJ
Acta Pharmacol Sin; 2017 Nov; 38(11):1512-1520. PubMed ID: 28880013
[TBL] [Abstract][Full Text] [Related]
19. Caffeic acid phenethyl ester surmounts acquired resistance of AZD9291 in non-small cell lung cancer cells.
Twum Y; Marshall K; Gao W
Biofactors; 2023; 49(6):1143-1157. PubMed ID: 37555475
[TBL] [Abstract][Full Text] [Related]
20. Exosome-derived miR-210 involved in resistance to osimertinib and epithelial-mesenchymal transition in EGFR mutant non-small cell lung cancer cells.
Hisakane K; Seike M; Sugano T; Yoshikawa A; Matsuda K; Takano N; Takahashi S; Noro R; Gemma A
Thorac Cancer; 2021 Jun; 12(11):1690-1698. PubMed ID: 33939301
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]